rss
J Clin Pathol 2009;62:542-546 doi:10.1136/jcp.2008.059717
  • Original article

HER-2/neu analysis in breast cancer bone metastases

  1. J Zustin1,
  2. K Boddin1,
  3. M C Tsourlakis1,
  4. E Burandt1,
  5. M Mirlacher1,
  6. F Jaenicke2,
  7. J Izbicki3,
  8. W Ruether4,
  9. J M Rueger5,
  10. C Bokemeyer6,
  11. R Simon1,
  12. G Sauter1
  1. 1
    Institute of Pathology, University Medical Center Hamburg-Eppendorf, Germany
  2. 2
    Department of Gynecology, University Medical Center Hamburg-Eppendorf, Germany
  3. 3
    Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Germany
  4. 4
    Department of Orthopaedics, University Medical Center Hamburg-Eppendorf, Germany
  5. 5
    Department of Trauma, Hand and Reconstructive Surgery, University Medical Center Hamburg-Eppendorf, Germany
  6. 6
    II. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Germany
  1. Dr J Zustin, Institute of Pathology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; j.zustin{at}uke.uni-hamburg.de
  • Accepted 23 January 2009

Abstract

Background: HER-2 is the target for antibody-based treatment of breast cancer (trastuzumab), which is highly successful in both advanced disease and the adjuvant setting. HER-2 can be analysed by fluorescence in situ hybridisation (FISH) for gene amplification or immunohistochemistry (IHC) for protein overexpression.

Aim: As both methods are known to be influenced by previous tissue processing, to analyse the applicability of both FISH and IHC to decalcified bone metastases of breast cancer.

Methods: A tissue microarray (TMA) was constructed from 149 breast cancer bone metastases. Consecutive TMA sections were analysed by FISH (PathVysion) and IHC (HercepTest).

Results: FISH analysis was interpretable in 113 (85.0%) cases. Amplification was seen in 14 (12.4%) interpretable metastases. HER-2 positivity on IHC analysis was 3+ in 9.8% of cases and 2+ in 11.3%. A comparison of the two techniques revealed high concordance. Of the 14 cases of amplification, 10 (71%) showed 3+ IHC staining, two (14%) showed 2+, one (7%) showed 1+, and one (7%) showed 0+. Three of the four amplified cases that did not show 3+ IHC staining had an equivocal FISH result, with a HER-2/centromere 17 ratio of 1.8–2.2. Of the 13 cases that showed IHC 3+ staining, amplification was present in 10 (77%).

Conclusions: HER-2 FISH analysis has an excellent success rate in highly standardised EDTA-decalcified bone metastases, suggesting that this method is easily applicable to decalcified tissues. The high concordance between IHC and FISH suggests that HER-2 IHC may be equally applicable to EDTA-treated tissues as to the usual formalin-fixed tissues.

Footnotes

  • Competing interests: None.

This Article

  1. Abstract
  2. Full text
  3. PDF

Responses

  1. Submit a response
  2. No responses published

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.